Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Today, the Swiss pharma titan announced the results of its Phase III VISION study, where 177Lu-PSMA-617 plus best standard of care (SOC) met both of its primary endpoints.
Organon’s focus will center on reproductive health, health conditions, and issues unique to women and diseases that disproportionately impact women.
AbbVie has been the target of multiple legal inquiries and challenges of its pricing and patent protections. Now, a U.S. senator is taking a gander at the company’s taxes.
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.
venBio Global Strategic Fund IV will invest primarily in drug companies focused on developing therapies for unmet medical needs.
Alzheimer’s patients and their families wait with hope that this will mean some offer of treatment, while physicians that treat Alzheimer’s patients are mulling the implications of the drug, often with hesitancy and skepticism.
Shares of Protagonist Therapeutics climbed nearly 4% in premarket trading after the company announced its lead drug candidate rusfertide snagged Breakthrough Therapy Designation from the U.S. FDA.
A well-designed career development program provides the right guidance and training for workers to improve their professional careers.
Do you know that growing emotional intelligence at workplace can be beneficial for career growth? If not, have a look at the article and learn some tips.
The nation’s top science adviser believes the country’s renewed enthusiasm for science may pave the way for plug-and-play vaccines that can nullify the next pandemic before it starts.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Venture capitalist Chamath Palihapitiya is raising $800 million to finance four more special purpose acquisition companies that will be focused on taking biotech companies public.